Stelara

This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.

New data keeps AbbVie’s star pipeline therapies on track

The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were

Latest news

BMS psoriasis drug hits the mark in phase II

including Johnson &Johnson’s Stelara (ustekinumab) and follow-up Tremfya (guselkumab), Sun Pharma’s Ilumya (tildrakizumab) and AbbVie’s recently-filed risankizumab.
AstraZeneca’s Lupus treatment misses mark in trial

Its blockbuster Stelara produced encouraging phase II results in the disease last November, while Gilead is working with Verily on an early stage research project to better understand the disease.
UK, Germany back routine use of J&J’s Tremfya

Tremfya (guselkumab) is a follow-up to J&J’s IL-23/IL-12 inhibitor Stelara (ustekinumab) that rakes in blockbuster revenues but is facing the threat of competition from newer ... Stelara was a $4bn product for J&J’s Janssen Pharma unit last year, but
Sun Pharma passes milestone with novel psoriasis drug approval

Johnson &Johnson's IL-12/IL-23 blocker Stelara (ustekinumab) was the first interleukin drug to reach the market and swiftly reached blockbuster sales level, and has since been joined by
AbbVie reports more solid data for would-be psoriasis blockbuster

AbbVie reports more solid data for would-be psoriasis blockbuster. Risankizumab showed to be more effective in plaque psoriasis patients than J&J’s Stelara. ... A pair of phase III trials pitting risankizumab against Johnson &Johnson’s older

More from news
Approximately 14 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Taking a strategic approach

Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Back to the future

Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager / Account Director: Competative

Scientific Director / Editorial Team Leader: Great salary and benefits

Events Manager – Med Comms – Surrey: Salary TBC

Medical Writers: Competitive Salary and Benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Associate Editorial Director – Med Comms – London: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Associate Director, Market Access & HEOR – North-West: Negotiable

Senior Account Director development role to Business Director, H...: Excellent package

Programme Director, Healthcare PR, Highly competitive package: Highly Competitive package

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Senior Account Executive, London, Medical Communications: Excellent package

Account Manager / Senior Account Manager: 35, 000-40, 000

New Business Director - PR: Competitive Salary and benefits

Account Director: Excellent benefits

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director: £48, 000 - £60, 000

Project / Account Manager (Medical Education): Salary TBC

Senior Medical Writer (Remote Working): Competitive Salary Offered

Senior Medical Writer: Competitive Salary

Medical Writers Required – Cheshire: DOE

Subscribe to our email news alerts

PMHub

Add my company

Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award: The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare: Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer: Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...